## Clinical Profile of Tislelizumab in Chinese Patients With MSI-H or dMMR Solid Tumors: Preliminary Results From an Indication-Expansion Cohort

Lin Shen<sup>1</sup>; Ying Yuan<sup>2</sup>; Tianshu Liu<sup>3</sup>; Yongqian Shu<sup>4</sup>; Jifang Gong<sup>1</sup>; Jian Li<sup>5</sup>; Zuobai Wang<sup>5</sup>; Chenlu Wei<sup>5</sup>; Xin Li<sup>5</sup>; Yuxian Bai<sup>6</sup>


<sup>1</sup>Peking University Cancer Hospital & Institute, Beijing, China; <sup>2</sup>The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China; <sup>3</sup>Zhongshan Hospital of Fudan University, Shanghai, China; <sup>4</sup>Jiangsu Province Hospital, Nanjing, China; <sup>5</sup>BeiGene (Beijing) Co., Ltd., Beijing, China; <sup>6</sup>Harbin Medical University Cancer Hospital, Harbin, China



2018年csco年会 厦门

## Relationship Between MSI Status and Immunologic Response

- Tumors with DNA mismatch repair deficiency (dMMR) and high microsatellite instability (MSI-H) are sensitive to PD-1 blockade
  - Tumors with MSI-H and dMMR have a significant upregulation of immune checkpoint proteins (including PD-1 and PD-L1), which enables them to survive




2018年csco年会 厦门

## Tislelizumab: A Uniquely Engineered Anti–PD-1 Monoclonal Antibody

- Tislelizumab is a humanized IgG4 monoclonal antibody with high affinity/specificity for PD-1
- Tislelizumab was specifically engineered to minimize binding to FcvR on macrophages, thereby abrogating antibodydependent T-cell clearance, a potential mechanism of resistance to anti-PD-1 therapy

厦门

2018年CSCO年会



No bridging  $Fc\gamma R^+$  cells and no activating PD-1 pathway

Figure modified from Dahan R, et al. *Cancer Cell*. 2015;28:285–295. **Abbreviations:** Ab, antibody; PD-1, programmed cell death-1.



# Design of BGB-A317-102 Study: Ongoing, Phase 1/2 Study of Tislelizumab in Chinese Patients

200 mg Q3W RP2D Here, we report the preliminary results from the phase 2 cohorts

1: Dose verification\*

(indication expansion) of this


multicenter clinical study of

tislelizumab in Chinese patients with

**MSI-H or dMMR solid tumors** 

Abbreviations: CRC, colorectal cancer; DLT, dose-limiting toxicity; HCC, he patocellular carcinoma; HNSCC, he ad and neck squamous cell carcinoma; dMMR, mismatch re pair deficiency; MSI-H, microsatellite instability high; NSCLC, non-small cell lung cancer; PD-L1, programmed cell death ligand-1; Q3W, every 3 weeks; RP2D, recommended phase 2 dose; SCNEC, small cell ne uroendocrine carcinoma; TNBC, tri ple-negative breast carcinoma.

2018年csco年会 厦门



**‡MSH-H and dMMR is defined based** on local assessment

## Patient Demographics and Baseline Disease Characteristics

- As of 11 May 2018, 22 patients have been enrolled
  - A total of 16 patients had a centrally confirmed MSI-H/dMMR tumor assessed by PCR or IHC
- The study population was primarily male (54%) with a median age of 54 years;
  82% had received ≥1 prior line of systemic therapy and colorectal cancer was the most common primary tumor type

	MSI-H/dMMR* (n=16)	Other (n=6)	Overall (N=22)
Median age, years (range)	60.5 (38, 74)	47.5 (37, 71)	54.0 (37, 74)
Male, n (%)	6 (37.5)	6 (100)	12 (54.5)
Primary site of tumor, n (%)			
CRC	14 (87.5)	6 (100)	20 (90.9)
GC	1 (6.3)	0 (0)	1 (4.5)
Unknown/ missing	1 (6.3)	0 (0)	1 (4.5)
Prior lines of systemic therapy, median (range)	2 (0, 5)	2.5 (1, 7)	2 (0, 7)
Number of prior anticancer therapy regimens, n (%)			
0	4 (25.0)	0 (0)	4 (18.2)
1	3 (18.8)	1 (16.7)	4 (18.2)
2	6 (37.5)	2 (33.3)	8 (36.4)
≥3	3 (18.8)	3 (50.0)	6 (27.3)
Median study follow-up duration, months (range)	4.4 (1.7, 10.7)	3.9 (0.10, 9.8)	4.4 (0.10, 10.7)
*Confirmed by central laboratory. Abbreviations: CRC, colorectal cancer; GC, gastric cancer; dMMR, mism	natch repair-deficient; MSI-H, micr	osatellite instability high.	

## **Patient Disposition**

- As of the data cut-off, a total of 10 of the 22 patients (45.5%) remain on treatment; the majority (n=9) have a confirmed MSI-H/dMMR tumor
  - Disease progression was the most common reason for treatment discontinuation
  - One patient discontinued due to an unrelated grade 3 lower gastrointestinal haemorrhage
  - Two patients discontinued due to death; both deaths were due to disease progression and considered unrelated to tislelizumab
- Across the study, median treatment duration of tislelizumab was 2.2 months (range: 0.69–11.1 months)
  - Treatment duration was higher in patients with tumors with confirmed MSI-H/dMMR than tumors with confirmed non-MSI-H/non-dMMR (3.6 vs 2.1 months)

MSI-H/dMMR* (n=16)	Other (n=6)	Overall (N=22)
9 (56.3)	1 (16.7)	10 (45.5)
7 (43.7)	5 (83.3)	<b>12 (54.4</b> )
1 (6.3)†	0 (0)	1 (4.5)
1 (6.3)	1 (16.7)	2 (9.1)
1 (6.3)	0 (0)	1 (4.5)
4 (25.0)	4 (66.7)	8 (36.4)
3.6 (1.3, 11.1)	2.1 (0.69, 4.1)	2.2 (0.69, 11.1)
4.4 (1.7, 10.7)	3.9 (0.10, 9.8)	4.4 (0.10, 10.7)
	(n=16) 9 (56.3) 7 (43.7) 1 (6.3) <sup>†</sup> 1 (6.3) 1 (6.3) 4 (25.0) 3.6 (1.3, 11.1)	(n=16)(n=6)9 (56.3)1 (16.7)7 (43.7)5 (83.3)1 (6.3) <sup>†</sup> 0 (0)1 (6.3)1 (16.7)1 (6.3)0 (0)4 (25.0)4 (66.7)3.6 (1.3, 11.1)2.1 (0.69, 4.1)

\*Confirmed by central laboratory; †Grade 3 lower gastrointestinal hemorrhage unrelated to tislelizumab. Abbreviations: AE, adverse event; dMMR, mismatch repair-deficient; MSI-H, microsatellite instability high.

Data cut-off: 11 May 2018

## Tislelizumab Response in Patients With Confirmed MSI-H/dMMR Tumors

- Fourteen patients with centrally confirmed MSI-H/dMMR tumors were evaluable for antitumor activity per RECIST v1.1 criteria
  - Across these 14 patients, the objective response rate was 28.6%
- Progressive disease was the best response in the three patients centrally negative for MSI-H/dMMR who were evaluable according to RECIST v1.1

Response, n (%)	MSI-H/dMMR (N=14)
Best overall response per RECIST v1.1 (confirmed)	
Complete response (CR)	0 (0.0)
Partial response (PR)	4 (28.6)
Stable disease (SD)	4 (28.6)
Progressive disease (PD)	6 (42.9)
<b>Objective response rate (CR+PR), % (95% CI)</b>	28.6 (8.39, 58.10)


Disease assessment by radiographic imaging was performed every 9 weeks during first 12 months and every 12 weeks thereafter. Abbreviations: CI, confidence interval; dMMR, mismatch repair-deficient; MSI-H, microsatellite instability high.

2018年CSCO年会

厦II



## Best Overall Response to Tislelizumab in Evaluable Patients With Confirmed MSI-H/dMMR Solid Tumors




Abbreviations: CRC, colorectal cancer; CUP, carcinomas of unknown primary; GC, gastric cancer; dMMR, mismatch repair-deficient; MSI-H, microsatellite instability high.

2018年CSCO年会

厦门



### Duration of Tislelizumab Treatment and Response in Evaluable Patients With Confirmed MSI-H/dMMR Solid Tumors




Abbreviations: CRC, colorectal cancer; CUP, carcinomas of unknown primary; GC, gastric cancer; dMMR, mismatch repair-deficient; MSI-H, microsatellite instability high.

2018年CSCO年会

厦门



### Duration of Tislelizumab Treatment and Response in Responders With Confirmed MSI-H/dMMR colorectal cancer




Abbreviations: DoR, duration of response; CRC, colorectal cancer; dMMR, mismatch repair-deficient; MSI-H, microsatellite instability high.

2018年CSCO年会

厦门



## Case Example 1: Radiographic Images of a Patient With MSI-H/dMMR CRC



**Abbreviations:** CR, Complete response; mFOLFOX, L-OHP + 5-Fu + LV; PD, progressive disease; PR, partial response; SLD, sum of the lesion diameters.

2018年CSCO年会 厦门

## **Case Example 2: Radiographic Images of a** Patient With MSI-H/dMMR CRC


- **Gender:** Female
- Age: 67 years ٠
- Metastases: Lymph ٠ nodes, Lung, Peritoneum, Ascites
- **Prior systemic** treatments: None
- Best overall response: ٠ PR

Abbreviations: CR, Complete response; PD, progressive disease; PR, partial response; SLD, sum of the lesion diameters.

2018年CSCO年会 厦门

### **Baseline**

**Week 27** 



	Baseline	Week 27
Target lesion SLD (mm)	40	15
Non Target Lesion		Non-CR/Non-PD
New Lesion		None

## **Adverse Events Considered Related to** Tislelizumab

- As of 11 May 2018, 18 of the 22 ۲ patients experienced  $\geq 1$ treatment-related AE (TRAE)
- The most common TRAEs were ۲ related to changes in clinical laboratory value (eg, increased bilirubin; increased transaminase)
  - − No TRAE was  $\geq$ 3 grade in severity

#### 2018年CSCO年会 厦门

#### Treatment-Related AEs Occurring in ≥2 Patients

	Overall	
	All Grades (N=22)	Grade ≥3 (N=22)
Subjects who experienced ≥1 TRAE	18 (81.2)	0 (0)
Increased bilirubin	8 (36.4)	0 (0)
Increased conjugated bilirubin	5 (22.7)	0 (0)
Increased blood bilirubin	4 (18.2)	0 (0)
Increased unconjugated blood bilirubin	2 (9.1)	0 (0)
Transaminases increased	6 (27.3)	0 (0)
Increased AST	5 (22.7)	0 (0)
Increased ALT	4 (18.2)	0 (0)
Anemia	5 (22.7)	0 (0)
Increased blood creatine phosphokinase	5 (22.7)	0 (0)
Decreased WBC and/or neutrophil count	4 (18.2)	0 (0)
Decreased WBC count	3 (13.6)	0 (0)
Decreased neutrophil count	2 (9.1)	0 (0)
Cough	3 (13.6)	0 (0)
Diarrhea	3 (13.6)	0 (0)
Proteinuria	3 (13.6)	0 (0)
Pyrexia	3 (13.6)	0 (0)
Fatigue	2 (9.1)	0 (0)
Data presented as n (%). Abbreviations: ALT, alanine aminotransferase; AST, as partate aminotransferase; TRAE, treatment-related adverse event; WBC, white blood cell. Data cut-off: 11 May 2018		

## Immune-Related Adverse Events Regardless of Attribution

- A total of 13 patients experienced immune-related AEs (irAEs)\*
  - The most common irAEs (defined as occurring in ≥10% of patients) were increased AST (n=5), increased conjugated bilirubin (n=5), increased blood creatine phosphokinase (n=5), increased ALT (n=4), increased blood bilirubin (n=4), and diarrhea (n=3)
  - All irAEs were Grade ≤2 in severity

厦门

2018年CSCO年会

### Immune-related AEs Occurring in ≥2 Patients

	Overall	
	All grades (N=22)	Grade ≥3 (N=22)
Subjects with ≥1 immune-related AE	13 (59.1)	0 (0)
Increased bilirubin	8 (36.4)	0 (0)
Increased conjugated bilirubin	5 (22.7)	0 (0)
Increased blood bilirubin	4 (18.2)	0 (0)
Increased unconjugated blood bilirubin	2 (9.1)	0 (0)
Transaminases increased	6 (27.3)	0 (0)
Increased AST	5 ( 22.7)	0 (0)
Increased ALT	4 ( 18.2)	0 (0)
Increased blood creatine phosphokinase	5 (22.7)	0 (0)
Diarrhea	3 (13.6)	0 (0)

Data presented as n (%).

**Abbreviations:** AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

\*Treatment-related adverse events reported in this study were categorized as immune related according to a predefined list of terms from the study sponsor



## Summary


- Preliminary data suggest tislelizumab may have antitumor activity in patients with MSI-H/dMMR tumors
  - As of the cut-off date, the objective response rate was ~29%; median duration of response was still maturing
- Tislelizumab was generally well tolerated in this subgroup of patients and demonstrated a safety profile consistent with what has been previously reported
  - Overall, 45.5% of patients (n=10/22) remained on treatment at the 11 May 2018 data cut-off
    - Disease progression was the most common reason for treatment discontinuation
- These data support the continued development of tislelizumab as a treatment for patients with MSI-H/dMMR tumors
  - A phase 2 study of single-agent tislelizumab in Chinese patients with previously treated locally advanced unresectable or metastatic MSI-H or dMMR solid tumors is ongoing (CTR20180867)



2018年CSCO年会 厦门

## Ongoing BGB-A317-209 Study (CTR20180867)

A **Single-Arm, Multi-Center, Open-Label, Phase 2 Study** to Evaluate Efficacy and Safety of Tislelizumab (BGB-A317), an anti-PD-1 Monoclonal Antibody, as Monotherapy in Patients with Previously-Treated Locally Advanced Unresectable or Metastatic MSI-H or dMMR Solid Tumors



#### **Primary endpoint:**

• Objective response rate (ORR) assessed by Independent Review Committee per RECIST v1.1

#### Secondary endpoints:

- Duration of Response (DoR), Time to Response (TTR), Progression-free Survival (PFS), Disease control rate (DCR) assessed by Independent Review Committee per RECIST v1.1
- Overall survival
- Objective response rate (ORR), Duration of response (DoR), Time to response (TTR), Progression-free survival (PFS), Disease control rate (DCR) evaluated by the Investigator per RECIST v1.1
- Safety and tolerability assessment





The authors wish to acknowledge the investigative center study staff and study patients, as well as recognize those from BeiGene, Ltd. who have substantially contributed to the development of this presentation.

BeiGene, Ltd. provided financial support for this presentation, including writing and editorial assistance by Dr Regina Switzer of SuccinctChoice Medical Communications, Chicago, IL.



